Eulysis UK Limited announced today that it is a Grand Challenges Explorations winner. Grand Challenges is an initiative funded by the Bill and Melinda Gates Foundation. Spyridon-Edouard Tsakas, a 2010 graduate of the Business School's MSc in International Business and Emerging Markets Programme, is Founder and President of Eulysis and will pursue an innovative global health and development research project, titled Single Vial System (SVS).

To receive funding, Spyridon-Edouard demonstrated in a two-page online application a bold idea in one of five critical global heath and development topic areas that included agriculture development, immunization and nutrition. Eulysis UK's Single Vial System (SVS) is an innovative device designed to solve several major inefficiencies in the current state of vaccine delivery. SVS offers optimised storage efficiency for immunisation supply systems comprised of vaccines containing a lyophilized active agent(s) and a diluent for reconstitution. Among the most significant benefits include simpler reconstitution and administration combined with a decreased risk of contamination both due to the fact that the entire reconstitution process occurs within a single air-tight vial as opposed to the two used presently. Currently, vaccines comprising lyophilized active agent(s) and diluent for reconstitution are produced, transported and stored in two vials; this leads to unnecessary burden on limited cold chain storage space as well as unnecessary raw material consumption and disposal bearing a negative impact on the environment. Imagine the potential to use the same truck that can currently transport and deliver 1,000,000 vaccines to a remote village now being able to transport and deliver 2,000,000 vaccines without any modification.

Spyridon "Ross" Tsakas is an innovative, self-made entrepreneur with diverse start-up, product and market development experience. He is the Founder and President of Eulysis Group based at the Roslin Biocentre in Scotland.  He is the recipient of numerous awards including an Enterprise Fellowship through the Royal Society of Edinburgh and Scottish Enterprise, the Prince's Scottish Youth Business Trust's Innovation Fund, Cultural Enterprise Office's Starter for 6 Program, a Finalist for both the Most Promising Young Life Science Company and Innovation of the Year Awards for 2012 through Nexxus Scotland and Commended by Edinburgh Chamber of Commerce as the Most Promising Business of the Year 2012, he is a connoisseur of the Life Science industry both in the UK and abroad.
 

Posted